var data={"title":"Pulmonary lymphomatoid granulomatosis","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Pulmonary lymphomatoid granulomatosis</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/contributors\" class=\"contributor contributor_credentials\">Talmadge E King, Jr, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/contributors\" class=\"contributor contributor_credentials\">Kevin R Flaherty, MD, MS</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/contributors\" class=\"contributor contributor_credentials\">Helen Hollingsworth, MD</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Sep 12, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary lymphomatoid granulomatosis (PLG) is an uncommon pulmonary disorder characterized by multiple pulmonary nodular lesions with lymphocytic invasion of vascular walls on biopsy. Averill Liebow and colleagues first described PLG as a clinicopathologic entity in 1972 [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/1\" class=\"abstract_t\">1</a>]. Since that time, the clinical implications of this lesion have remained controversial, as evidenced by a long list of competing synonyms including angiocentric immunoproliferative lesion and angiocentric lymphoma [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2-4\" class=\"abstract_t\">2-4</a>]. Some have argued that the histopathologic pattern of lymphomatoid granulomatosis, which can occur in pulmonary and extrapulmonary tissue, is a nonspecific manifestation of diverse pathogenetic conditions, including autoimmunity, infection, and malignancy [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p>It is generally believed that PLG represents a form of lymphoproliferative disorder. The World Health Organization (WHO) classification scheme places lymphomatoid granulomatosis under the generic heading of B cell proliferations of uncertain malignant potential [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>]. These lymphoproliferative disorders are in the family of Epstein-Barr virus (EBV)-associated B cell lymphomas [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5-8\" class=\"abstract_t\">5-8</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-treatment-of-epstein-barr-virus-infection#H12\" class=\"medical medical_review\">&quot;Clinical manifestations and treatment of Epstein-Barr virus infection&quot;, section on 'Lymphoproliferative disorders'</a> and <a href=\"topic.htm?path=epidemiology-clinical-manifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma#H763094\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma&quot;, section on 'Lymphomatoid granulomatosis'</a>.)</p><p>In addition to PLG, the lung is the primary organ of involvement in a spectrum of lymphocytic and lymphoproliferative disorders. These include lymphoid interstitial pneumonia, plasma cell interstitial pneumonia, angioimmunoblastic lymphadenopathy, and primary pulmonary lymphoma [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/9,10\" class=\"abstract_t\">9,10</a>]. Pulmonary lymphomatoid granulomatosis will be reviewed here. Clinical aspects of other pulmonary lymphocytic and lymphoproliferative disorders are discussed separately. (See <a href=\"topic.htm?path=lymphoid-interstitial-pneumonia-in-adults\" class=\"medical medical_review\">&quot;Lymphoid interstitial pneumonia in adults&quot;</a> and <a href=\"topic.htm?path=inflammatory-myofibroblastic-tumor-plasma-cell-granuloma-of-the-lung\" class=\"medical medical_review\">&quot;Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-peripheral-t-cell-lymphoma-not-otherwise-specified#H10\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified&quot;, section on 'Angioimmunoblastic T cell lymphoma'</a> and <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-extranodal-marginal-zone-lymphoma-of-mucosa-associated-lymphoid-tissue-malt\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary lymphomatoid granulomatosis generally presents between the ages of 30 and 50, although patients can be affected at any age [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/4,11-17\" class=\"abstract_t\">4,11-17</a>]. It is predominantly seen in men, with an estimated male to female ratio of at least 2:1 [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5,18\" class=\"abstract_t\">5,18</a>]. The effects of race and geography on disease incidence are not known, although a higher diagnosis rate is reported in Western countries [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary lymphomatoid granulomatosis (PLG) appears to be associated with Epstein-Barr virus (EBV) infection in most if not all cases [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5,6\" class=\"abstract_t\">5,6</a>]. A small number of cases show no demonstrable evidence of EBV infection, and may represent a distinct form of peripheral T cell lymphoma [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/9\" class=\"abstract_t\">9</a>]. Alternatively, these cases may reflect grade 1 disease with infrequent EBV-positive cells that were not detected [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/19-21\" class=\"abstract_t\">19-21</a>]. (See <a href=\"#H13\" class=\"local\">'Grading'</a> below and <a href=\"topic.htm?path=epidemiology-clinical-manifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma#H763094\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma&quot;, section on 'Lymphomatoid granulomatosis'</a>.)</p><p>In addition, PLG can be seen in patients with an underlying immunodeficiency (eg, Wiskott-Aldrich, X-linked immunodeficiency, immunosuppression post allogeneic organ transplantation) or a lymphoproliferative disorder [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/11,12,22-24\" class=\"abstract_t\">11,12,22-24</a>]. These immune defects may lead to an abnormal host response to EBV infection, resulting in lymphomatoid granulomatosis rather than clearance of the viral infection [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2,5\" class=\"abstract_t\">2,5</a>].</p><p>PLG may develop as a consequence of the immunosuppression induced by certain medications. Rare cases of PLG have been reported in patients being treated with <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>, and <a href=\"topic.htm?path=imatinib-drug-information\" class=\"drug drug_general\">imatinib</a> with resolution sometimes following cessation of the medication [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/25-32\" class=\"abstract_t\">25-32</a>].</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL PRESENTATION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The lung is the most commonly involved organ (&gt;90 percent) [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>]. The skin (25 to 50 percent), kidney (32 percent), and neurologic system (20 to 30 percent) may be affected concurrently or independently [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5,11\" class=\"abstract_t\">5,11</a>]. Less commonly, patients have involvement of other organ systems, such as the liver, spleen, lymph nodes, eyes, hard palate, gastrointestinal tract, and genitourinary tract [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2,5,11,33-36\" class=\"abstract_t\">2,5,11,33-36</a>]. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma#H763094\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma&quot;, section on 'Lymphomatoid granulomatosis'</a>.)</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h2\">Symptoms and signs</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The most common presenting symptoms and signs are cough (60 percent of patients), fever (60 percent), <span class=\"nowrap\">rash/nodules</span> (40 percent), malaise (35 percent), weight loss (35 percent), neurologic abnormalities (30 percent), dyspnea (30 percent), and chest pain (15 percent) [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/11\" class=\"abstract_t\">11</a>]. Rarely, patients may be asymptomatic.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h2\">Physical examination</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Physical examination of the lungs is generally normal. Extrapulmonary involvement may be more readily apparent, as examination of the skin can reveal rash, subcutaneous nodules, or ulceration. The skin lesions are generally painless, but can occasionally be tender and pruritic. Neurologic involvement is often manifested by ataxia, cranial nerve abnormalities, and peripheral neuropathy [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/37\" class=\"abstract_t\">37</a>].</p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h2\">Laboratory studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Laboratory studies are generally nondiagnostic. The complete blood cell count is generally normal with occasional mild leukocytosis or leukopenia [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/1\" class=\"abstract_t\">1</a>]. Nonspecific abnormalities in immunoglobulins (usually increases in IgG and IgM) are seen in the majority of patients [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/11,12\" class=\"abstract_t\">11,12</a>]. In patients with evidence of neurologic disease, lumbar puncture commonly reveals pleocytosis with an elevated protein level [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2,38\" class=\"abstract_t\">2,38</a>].</p><p>Serologic evidence of previous Epstein-Barr virus (EBV) infection is generally present, although the heterophile test may be negative [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/11,15\" class=\"abstract_t\">11,15</a>]. The serologic evaluation of EBV infection is discussed separately. (See <a href=\"topic.htm?path=infectious-mononucleosis-in-adults-and-adolescents#H18\" class=\"medical medical_review\">&quot;Infectious mononucleosis in adults and adolescents&quot;, section on 'Diagnosis'</a>.)</p><p>In patients with evidence of neurologic disease, lumbar puncture commonly reveals pleocytosis with an elevated protein level [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2,39\" class=\"abstract_t\">2,39</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-treatment-of-epstein-barr-virus-infection\" class=\"medical medical_review\">&quot;Clinical manifestations and treatment of Epstein-Barr virus infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h2\">Lung function testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>No characteristic pulmonary function test abnormalities have been reported [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/4\" class=\"abstract_t\">4</a>]. Hypoxemia and chronic respiratory alkalosis have been found in the majority of patients who have had arterial blood gas testing [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/4\" class=\"abstract_t\">4</a>]. (See <a href=\"topic.htm?path=overview-of-pulmonary-function-testing-in-adults\" class=\"medical medical_review\">&quot;Overview of pulmonary function testing in adults&quot;</a> and <a href=\"topic.htm?path=oxygenation-and-mechanisms-of-hypoxemia\" class=\"medical medical_review\">&quot;Oxygenation and mechanisms of hypoxemia&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Imaging studies</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chest radiography typically reveals multiple poorly defined nodules <span class=\"nowrap\">and/or</span> masses in the mid- and lower-lung zones; diffuse reticular abnormalities may also be present [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2,4,18,39\" class=\"abstract_t\">2,4,18,39</a>].</p><p>Chest computed tomography usually shows both well and poorly-defined nodules throughout both lungs. Most lesions are less than 1 cm in diameter, but larger cavitary masses have been reported [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/18,40\" class=\"abstract_t\">18,40</a>]. Nodules are preferentially located along the bronchovascular structures or interlobular septa (<a href=\"image.htm?imageKey=PULM%2F52068%7EPULM%2F60848\" class=\"graphic graphic_diagnosticimage graphicRef52068 graphicRef60848 \">image 1A-B</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>]. Thin walled cystic lesions may also be present (<a href=\"image.htm?imageKey=PULM%2F71625\" class=\"graphic graphic_diagnosticimage graphicRef71625 \">image 2</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/18\" class=\"abstract_t\">18</a>]. (See <a href=\"topic.htm?path=differential-diagnosis-and-evaluation-of-multiple-pulmonary-nodules\" class=\"medical medical_review\">&quot;Differential diagnosis and evaluation of multiple pulmonary nodules&quot;</a> and <a href=\"topic.htm?path=high-resolution-computed-tomography-of-the-lungs\" class=\"medical medical_review\">&quot;High resolution computed tomography of the lungs&quot;</a>.)</p><p>A few case reports have reported variable uptake of 18F-fluorodeoxyglucose (18F-FDG) on positron emission tomographic (PET) scanning [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/41-43\" class=\"abstract_t\">41-43</a>].</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h1\">PATHOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>An accurate morphologic, immunophenotypic, and genetic analysis of involved tissue is essential for the diagnosis of pulmonary lymphomatoid granulomatosis (PLG) [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/24\" class=\"abstract_t\">24</a>].</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Morphology</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The histopathologic diagnosis of PLG requires a triad of polymorphic lymphoid infiltrates, transmural infiltration of arteries and veins by lymphoid cells (&quot;angiitis&quot;), and focal areas of necrosis within the lymphoid infiltrates (<a href=\"image.htm?imageKey=PULM%2F74089%7EPULM%2F61309\" class=\"graphic graphic_picture graphicRef74089 graphicRef61309 \">picture 1A-B</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/1\" class=\"abstract_t\">1</a>]. These areas of necrosis gave rise to the term &quot;granulomatosis;&quot; however, well-formed granulomas are typically absent [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p>The lymphoid infiltrate is typically composed of small lymphocytes, plasma cells, and a variable number of large atypical mononuclear cells. The majority of the small lymphocytes are T cells, while large atypical cells are usually B cells [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/44,45\" class=\"abstract_t\">44,45</a>]. In most cases, the T cells are polyclonal and represent a &quot;reactive,&quot; non-neoplastic population [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/46\" class=\"abstract_t\">46</a>]. Large atypical B cells, when present, represent the neoplastic component and show evidence of Epstein-Barr virus (EBV) infection with in situ hybridization [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5,8\" class=\"abstract_t\">5,8</a>]. The term &quot;lymphohistiocytic&quot; may be applied when histiocytes are present. (See <a href=\"topic.htm?path=clinical-manifestations-and-treatment-of-epstein-barr-virus-infection\" class=\"medical medical_review\">&quot;Clinical manifestations and treatment of Epstein-Barr virus infection&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Immunophenotype</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The EBV positive B cells typically express CD20 and may express CD30. The background lymphocytes are CD3 positive T cells with a preponderance that express CD4 rather than CD8 [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5,24\" class=\"abstract_t\">5,24</a>].</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h2\">Grading</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Histopathologic grading has shown a weak and inconsistent correlation with outcome in lymphomatoid granulomatosis [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/8,15\" class=\"abstract_t\">8,15</a>]. Three histopathologic grades have been proposed, based upon the proportion of EBV-positive large B lymphocytes present [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2,5\" class=\"abstract_t\">2,5</a>]. Grade 1 lesions are either devoid of or contain only scattered EBV-positive cells. It is unclear whether lesions devoid of EBV-positive B cells represent a distinct primary T cell disorder, or an exuberant response to rare (but not visualized) EBV-positive cells [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2,5,7\" class=\"abstract_t\">2,5,7</a>]. Grade 2 and 3 lesions have increasing numbers of EBV-positive large cells. Grade 3 lesions most closely resemble the clinical and pathologic features of other more conventional forms of diffuse large B cell lymphoma (DLBCL). (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H14\"><span class=\"h2\">Genetic features</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no single cytogenetic change that is characteristic of PLG. Generally, in grades 2 and 3 disease, B cell monoclonality can be demonstrated with testing of the immunoglobulin genes or Southern blot, whereas B cell clonality is inconsistent in grade 1 disease [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>]. Analysis of the T cell receptor gene shows polyclonality. Oncogene alterations have not been reported [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H15\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Since the clinical presentation of pulmonary lymphomatoid granulomatosis (PLG) is nonspecific, the diagnosis hinges on histopathology showing the classic triad (see <a href=\"#H11\" class=\"local\">'Morphology'</a> above). If the lung is the primary site of involvement, lung tissue is usually obtained by video-assisted thoracoscopic surgery or open thoracotomy, as transthoracic needle aspirate and transbronchial biopsy samples are too small for adequate evaluation. Immunohistochemical analysis that uses antibodies directed against B and T cell-associated antigens helps to determine the proportion and clonality of these cells. In situ hybridization is used to establish the presence of Epstein-Barr virus (EBV) positive B cells. The presence of large B cells showing the presence of EBV-positive cells by in situ hybridization with the EBER probe is now definitional for PLG [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/47\" class=\"abstract_t\">47</a>]. (See <a href=\"#H10\" class=\"local\">'Pathology'</a> above.)</p><p>The general evaluation of a patient with multiple pulmonary nodules is described separately. (See <a href=\"topic.htm?path=differential-diagnosis-and-evaluation-of-multiple-pulmonary-nodules\" class=\"medical medical_review\">&quot;Differential diagnosis and evaluation of multiple pulmonary nodules&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H16\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Pulmonary lymphomatoid granulomatosis (PLG) should be distinguished from granulomatosis with polyangiitis (Wegener&rsquo;s), as well as other forms of malignant lymphoma, especially extranodal <span class=\"nowrap\">NK/T</span> cell lymphoma, which is also associated with Epstein-Barr virus (EBV) infection but rarely involves the lung.</p><p>In lymphomatoid granulomatosis, prominent vascular infiltration with inflammatory cells and arterial narrowing are noted, but vessel wall necrosis, a feature of granulomatosis with polyangiitis, is generally minimal to absent. In addition, multinucleated giant cells are not seen in lymphomatoid granulomatosis, but are often seen in WG [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of granulomatosis with polyangiitis and microscopic polyangiitis&quot;</a>.)</p><p>A diagnosis of diffuse large B cell lymphoma (DLBCL) is made when a uniform population of large, atypical EBV-positive B cells is noted without a polymorphous background population of cells [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>]. (See <a href=\"topic.htm?path=epidemiology-clinical-manifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">&quot;Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma&quot;</a>.)</p><p><span class=\"nowrap\">NK/T</span> cell lymphoma, nasal type, is also associated with EBV infection [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>]. However, the EBV positive tumor cells in PLG are of B cell origin and thus positive for pan-B cell markers such as CD20; whereas the EBV positive cells in <span class=\"nowrap\">NK/T</span> cell lymphoma are T cells. (See <a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-extranodal-nk-t-cell-lymphoma-nasal-type\" class=\"medical medical_review\">&quot;Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H17\"><span class=\"h1\">STAGING</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>A formal staging system for pulmonary lymphomatoid granulomatosis (PLG) has not been reported, other than that used for non-Hodgkin lymphomas. However, it may be reasonable to assess the extent of disease in the lungs and other organ systems, using careful skin and neurologic examinations, and also thoracic and abdominal computed tomography (CT) scanning. The role of positron emission tomographic (PET) scanning using 18F-fluorodeoxyglucose (18F-FDG) for staging PLG is unclear, and PLG lesions do not always have increased uptake of 18F-FDG [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/41-43\" class=\"abstract_t\">41-43</a>]. The clinical relevance of such a staging approach is unknown. (See <a href=\"topic.htm?path=evaluation-staging-and-response-assessment-of-non-hodgkin-lymphoma\" class=\"medical medical_review\">&quot;Evaluation, staging, and response assessment of non-Hodgkin lymphoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H18\"><span class=\"h1\">NATURAL HISTORY AND PROGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The clinical course of lymphomatoid granulomatosis is variable [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/11,13\" class=\"abstract_t\">11,13</a>]. Approximately 20 percent of patients achieve remission without treatment [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2,11,48\" class=\"abstract_t\">2,11,48</a>]. However, the majority of patients have progressive disease.</p><p>In historical studies, mortality rates exceeded 50 percent with reported median survivals from the time of diagnosis ranging from 14 to 72 months [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/4,11\" class=\"abstract_t\">4,11</a>]. The presence of histopathologic grade 2 or 3 disease and the presence of neurologic disease appear to predict a worse outcome [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2,11\" class=\"abstract_t\">2,11</a>].</p><p class=\"headingAnchor\" id=\"H19\"><span class=\"h1\">MANAGEMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The choice of a treatment strategy should be based upon the history of using an inciting medication, the presence and severity of symptoms, the extent of extrapulmonary involvement, and the histopathologic grade of the lesion [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2,5,24,47,49\" class=\"abstract_t\">2,5,24,47,49</a>].</p><p>Patients who have been taking a medication associated with pulmonary lymphomatoid granulomatosis should stop the suspect medication; the chest computed tomography (CT) scan should be repeated periodically to look for changes in the extent of disease over the next several weeks to months [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p>Patients without symptoms and with low-grade (eg, Grades 1 and 2) disease confined to the lungs may reasonably be followed with serial clinical and radiological evaluations, as this group of patients can experience spontaneous remission [<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/5\" class=\"abstract_t\">5</a>]. Symptomatic patients, patients with more extensive disease (especially those with neurologic involvement), and patients with high-grade lesions should be referred to a hematology oncology specialist for consideration of treatment with chemotherapy.</p><p>In general, treatment options for pulmonary lymphomatoid granulomatosis follow those for diffuse large B cell lymphoma (DLBCL). However, a few case reports and case series have described promising results with the antiviral, antiproliferative cytokine <a href=\"topic.htm?path=interferon-alfa-2b-drug-information\" class=\"drug drug_general\">interferon alfa-2b</a>&nbsp;[<a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/15,16,50\" class=\"abstract_t\">15,16,50</a>]. The efficacy of this treatment compared with formal treatment for DLBCL is not known. Other proposed therapies include multiagent chemotherapy and anti-CD20 monoclonal antibodies (eg, <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">rituximab</a>). These options are discussed separately. (See <a href=\"topic.htm?path=initial-treatment-of-advanced-stage-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">&quot;Initial treatment of advanced stage diffuse large B cell lymphoma&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H20\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Pulmonary lymphomatoid granulomatosis likely represents a lymphoproliferative disorder in the family of Epstein-Barr virus (EBV)-associated B cell lymphomas. (See <a href=\"#H1\" class=\"local\">'Introduction'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Lymphomatoid granulomatosis presents between the ages of 30 and 50, although patients can be affected at any age. Men are more commonly affected than women, with an estimated male to female ratio of 2:1. (See <a href=\"#H2\" class=\"local\">'Epidemiology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The lung is the most commonly involved organ; the skin and neurologic system may be affected separately or concurrently. Involvement of other organs occurs, but is less common. (See <a href=\"#H4\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The most common presenting symptoms and signs include cough, fever, <span class=\"nowrap\">rash/nodules,</span> malaise, weight loss, neurologic abnormalities, dyspnea, and chest pain. (See <a href=\"#H4\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chest imaging studies typically show multiple ill-defined nodular opacities. (See <a href=\"#H4\" class=\"local\">'Clinical presentation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The histopathologic diagnosis of lymphomatoid granulomatosis requires a triad of polymorphic lymphoid infiltrates, transmural infiltration of arteries and veins by lymphoid cells (&quot;angiitis&quot;), and focal areas of necrosis within the lymphoid infiltrates (well-formed granulomas are not present) (<a href=\"image.htm?imageKey=PULM%2F74089%7EPULM%2F61309\" class=\"graphic graphic_picture graphicRef74089 graphicRef61309 \">picture 1A-B</a>). Additional features include staining for EBV on in situ hybridization studies, polyclonality of T cells, and usually monoclonality of B cells. (See <a href=\"#H10\" class=\"local\">'Pathology'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The clinical course of lymphomatoid granulomatosis is variable, ranging from remission without treatment to death within 2 years from malignant lymphoma. (See <a href=\"#H18\" class=\"local\">'Natural history and prognosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The choice of a treatment strategy should be based upon the presence of symptoms, history of using an inciting medication, extent of extrapulmonary involvement, and careful assessment of the histopathologic grade of the lesion. When a medication (eg, <a href=\"topic.htm?path=azathioprine-drug-information\" class=\"drug drug_general\">azathioprine</a>, <a href=\"topic.htm?path=methotrexate-drug-information\" class=\"drug drug_general\">methotrexate</a>) is implicated, it should be stopped and the patient observed for changes in the extent of disease. (See <a href=\"topic.htm?path=initial-treatment-of-advanced-stage-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">&quot;Initial treatment of advanced stage diffuse large B cell lymphoma&quot;</a> and <a href=\"#H19\" class=\"local\">'Management'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>For asymptomatic patients with low-grade (eg, Grades 1 and 2) disease that is confined to the lungs, we suggest observation rather than immediate treatment, as some of these patients can experience a spontaneous remission (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Serial clinical and radiological evaluations are required during observation. (See <a href=\"#H19\" class=\"local\">'Management'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients who are symptomatic, have more extensive or progressive disease (eg, neurologic involvement), or have pathologically high-grade lesions are usually referred to a hematology oncology specialist for consultation. (See <a href=\"#H19\" class=\"local\">'Management'</a> above and <a href=\"topic.htm?path=initial-treatment-of-advanced-stage-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">&quot;Initial treatment of advanced stage diffuse large B cell lymphoma&quot;</a>.)</p><p/><p class=\"headingAnchor\" id=\"H22300596\"><span class=\"h1\">ACKNOWLEDGMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The editorial staff at UpToDate would like to acknowledge Dr. Harold Collard, who contributed to an earlier version of this topic review.</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/1\" class=\"nounderline abstract_t\">Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis. Hum Pathol 1972; 3:457.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/2\" class=\"nounderline abstract_t\">Jaffe ES, Wilson WH. Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. Cancer Surv 1997; 30:233.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/3\" class=\"nounderline abstract_t\">Myers JL. Lymphomatoid granulomatosis: past, present, ... future? Mayo Clin Proc 1990; 65:274.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/4\" class=\"nounderline abstract_t\">Pisani RJ, DeRemee RA. Clinical implications of the histopathologic diagnosis of pulmonary lymphomatoid granulomatosis. Mayo Clin Proc 1990; 65:151.</a></li><li class=\"breakAll\">Pittaluga S, Wilson WH, Jaffe ES. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC Press, Lyon 2008.</li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/6\" class=\"nounderline abstract_t\">Nicholson AG, Wotherspoon AC, Diss TC, et al. Lymphomatoid granulomatosis: evidence that some cases represent Epstein-Barr virus-associated B-cell lymphoma. Histopathology 1996; 29:317.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/7\" class=\"nounderline abstract_t\">Myers JL, Kurtin PJ, Katzenstein AL, et al. Lymphomatoid granulomatosis. Evidence of immunophenotypic diversity and relationship to Epstein-Barr virus infection. Am J Surg Pathol 1995; 19:1300.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/8\" class=\"nounderline abstract_t\">Guinee D Jr, Jaffe E, Kingma D, et al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol 1994; 18:753.</a></li><li class=\"breakAll\">Cosgrove GP, Schwartz MI. Lymphocytoplasmic infiltrations of the lung. In: Interstitial Lung Disease, 5th ed, Schwarz MI, King TE Jr (Eds), People&rsquo;s Medical Publishing House - USA, Hamilton 2011. p.1053.</li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/10\" class=\"nounderline abstract_t\">Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J 2002; 20:750.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/11\" class=\"nounderline abstract_t\">Katzenstein AL, Carrington CB, Liebow AA. Lymphomatoid granulomatosis: a clinicopathologic study of 152 cases. Cancer 1979; 43:360.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/12\" class=\"nounderline abstract_t\">Sordillo PP, Epremian B, Koziner B, et al. Lymphomatoid granulomatosis: an analysis of clinical and immunologic characteristics. Cancer 1982; 49:2070.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/13\" class=\"nounderline abstract_t\">Fauci AS, Haynes BF, Costa J, et al. Lymphomatoid Granulomatosis. Prospective clinical and therapeutic experience over 10 years. N Engl J Med 1982; 306:68.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/14\" class=\"nounderline abstract_t\">Koss MN, Hochholzer L, Langloss JM, et al. Lymphomatoid granulomatosis: a clinicopathologic study of 42 patients. Pathology 1986; 18:283.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/15\" class=\"nounderline abstract_t\">Wilson WH, Kingma DW, Raffeld M, et al. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood 1996; 87:4531.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/16\" class=\"nounderline abstract_t\">Oren H, Irken G, Kargi A, et al. A pediatric case of lymphomatoid granulomatosis with onset after completion of chemotherapy for acute myeloid leukemia. J Pediatr Hematol Oncol 2003; 25:163.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/17\" class=\"nounderline abstract_t\">Katzenstein AL, Doxtader E, Narendra S. Lymphomatoid granulomatosis: insights gained over 4 decades. Am J Surg Pathol 2010; 34:e35.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/18\" class=\"nounderline abstract_t\">Lee JS, Tuder R, Lynch DA. Lymphomatoid granulomatosis: radiologic features and pathologic correlations. AJR Am J Roentgenol 2000; 175:1335.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/19\" class=\"nounderline abstract_t\">Morice WG, Kurtin PJ, Myers JL. Expression of cytolytic lymphocyte-associated antigens in pulmonary lymphomatoid granulomatosis. Am J Clin Pathol 2002; 118:391.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/20\" class=\"nounderline abstract_t\">Lucantoni C, De Bonis P, Doglietto F, et al. Primary cerebral lymphomatoid granulomatosis: report of four cases and literature review. J Neurooncol 2009; 94:235.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/21\" class=\"nounderline abstract_t\">Nishihara H, Tateishi U, Itoh T, et al. Immunohistochemical and gene rearrangement studies of central nervous system lymphomatoid granulomatosis. Neuropathology 2007; 27:413.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/22\" class=\"nounderline abstract_t\">V&aacute;r&oacute;czy L, Gergely L, Szak&aacute;ll S, Ill&eacute;s A. Angiocentric lymphomatoid granulomatosis and severe hypogammaglobulinaemia. Haematologia (Budap) 2002; 32:535.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/23\" class=\"nounderline abstract_t\">Sebire NJ, Haselden S, Malone M, et al. Isolated EBV lymphoproliferative disease in a child with Wiskott-Aldrich syndrome manifesting as cutaneous lymphomatoid granulomatosis and responsive to anti-CD20 immunotherapy. J Clin Pathol 2003; 56:555.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/24\" class=\"nounderline abstract_t\">Song JY, Pittaluga S, Dunleavy K, et al. Lymphomatoid granulomatosis--a single institute experience: pathologic findings and clinical correlations. Am J Surg Pathol 2015; 39:141.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/25\" class=\"nounderline abstract_t\">Katherine Martin L, Porcu P, Baiocchi RA, et al. Primary central nervous system lymphomatoid granulomatosis in a patient receiving azathioprine therapy. Clin Adv Hematol Oncol 2009; 7:65.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/26\" class=\"nounderline abstract_t\">Joseph R, Chacko B, Manipadam MT, et al. Pulmonary lymphomatoid granulomatosis in a renal allograft recipient. Transpl Infect Dis 2008; 10:52.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/27\" class=\"nounderline abstract_t\">Pfistershammer K, Petzelbauer P, Stingl G, et al. Methotrexate-induced primary cutaneous diffuse large B-cell lymphoma with an 'angiocentric' histological morphology. Clin Exp Dermatol 2010; 35:59.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/28\" class=\"nounderline abstract_t\">Kameda H, Okuyama A, Tamaru J, et al. Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis. Clin Rheumatol 2007; 26:1585.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/29\" class=\"nounderline abstract_t\">Yazdi AS, Metzler G, Weyrauch S, et al. Lymphomatoid granulomatosis induced by imatinib-treatment. Arch Dermatol 2007; 143:1222.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/30\" class=\"nounderline abstract_t\">Barakat A, Grover K, Peshin R. Rituximab for pulmonary lymphomatoid granulomatosis which developed as a complication of methotrexate and azathioprine therapy for rheumatoid arthritis. Springerplus 2014; 3:751.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/31\" class=\"nounderline abstract_t\">Oiwa H, Mihara K, Kan T, et al. Grade 3 lymphomatoid granulomatosis in a patient receiving methotrexate therapy for rheumatoid arthritis. Intern Med 2014; 53:1873.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/32\" class=\"nounderline abstract_t\">Connors W, Griffiths C, Patel J, Belletrutti PJ. Lymphomatoid granulomatosis associated with azathioprine therapy in Crohn disease. BMC Gastroenterol 2014; 14:127.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/33\" class=\"nounderline abstract_t\">Shanti RM, Torres-Cabala CA, Jaffe ES, et al. Lymphomatoid granulomatosis with involvement of the hard palate: a case report. J Oral Maxillofac Surg 2008; 66:2161.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/34\" class=\"nounderline abstract_t\">Pereira AC, Oliveira TM, Nomelini RS, et al. Lymphomatoid granulomatosis of the vulva: case report with immunohistochemical analysis. J Obstet Gynaecol 2009; 29:255.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/35\" class=\"nounderline abstract_t\">Melegh Z, Sutak J, Whiteway A, et al. Lymphomatoid granulomatosis of the uterine cervix. Pathol Res Pract 2009; 205:371.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/36\" class=\"nounderline abstract_t\">Kappen JH, van Zaanen HC, Snelder SM, et al. Lymphomatoid granulomatosis with pulmonary and gastrointestinal involvement. BMJ Case Rep 2017; 2017.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/37\" class=\"nounderline abstract_t\">Mizuno T, Takanashi Y, Onodera H, et al. A case of lymphomatoid granulomatosis/angiocentric immunoproliferative lesion with long clinical course and diffuse brain involvement. J Neurol Sci 2003; 213:67.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/38\" class=\"nounderline abstract_t\">Collins S, Helme RD. Lymphomatoid granulomatosis presenting as a progressive cervical cord lesion. Aust N Z J Med 1989; 19:144.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/39\" class=\"nounderline abstract_t\">Bolaman Z, Kadik&ouml;yl&uuml; G, Polatli M, et al. Migratory nodules in the lung: lymphomatoid granulomatosis. Leuk Lymphoma 2003; 44:197.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/40\" class=\"nounderline abstract_t\">McCloskey M, Catherwood M, McManus D, et al. A case of lymphomatoid granulomatosis masquerading as a lung abscess. Thorax 2004; 59:818.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/41\" class=\"nounderline abstract_t\">Arai H, Oshiro H, Yamanaka S, et al. Grade I lymphomatoid granulomatosis with increased uptake of [18F] fluorodeoxyglucose in positron emission tomography: a case report. J Clin Exp Hematop 2009; 49:39.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/42\" class=\"nounderline abstract_t\">Kawai N, Miyake K, Nishiyama Y, et al. FDG-PET findings of the brain in lymphomatoid granulomatosis. Ann Nucl Med 2006; 20:683.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/43\" class=\"nounderline abstract_t\">Erickson BW, Cripe L, Rieger K, et al. A woman with facial papules and pulmonary nodules. Respiration 2007; 74:471.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/44\" class=\"nounderline abstract_t\">Nichols PW, Koss M, Levine AM, Lukes RJ. Lymphomatoid granulomatosis: a T-cell disorder? Am J Med 1982; 72:467.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/45\" class=\"nounderline abstract_t\">Lipford EH Jr, Margolick JB, Longo DL, et al. Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations. Blood 1988; 72:1674.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/46\" class=\"nounderline abstract_t\">Medeiros LJ, Peiper SC, Elwood L, et al. Angiocentric immunoproliferative lesions: a molecular analysis of eight cases. Hum Pathol 1991; 22:1150.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/47\" class=\"nounderline abstract_t\">Colby TV. Current histological diagnosis of lymphomatoid granulomatosis. Mod Pathol 2012; 25 Suppl 1:S39.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/48\" class=\"nounderline abstract_t\">James WD, Odom RB, Katzenstein AL. Cutaneous manifestations of lymphomatoid granulomatosis. Report of 44 cases and a review of the literature. Arch Dermatol 1981; 117:196.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/49\" class=\"nounderline abstract_t\">Roschewski M, Wilson WH. Lymphomatoid granulomatosis. Cancer J 2012; 18:469.</a></li><li><a href=\"https://www.uptodate.com/contents/pulmonary-lymphomatoid-granulomatosis/abstract/50\" class=\"nounderline abstract_t\">Richter C, Schnabel A, M&uuml;ller KM, et al. [Lymphomatoid granulomatosis--remission induction with interferon-alpha 2b]. Dtsch Med Wochenschr 1997; 122:1106.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 4324 Version 9.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H20\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">ETIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL PRESENTATION</a><ul><li><a href=\"#H5\" id=\"outline-link-H5\">Symptoms and signs</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">Physical examination</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">Laboratory studies</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">Lung function testing</a></li><li><a href=\"#H9\" id=\"outline-link-H9\">Imaging studies</a></li></ul></li><li><a href=\"#H10\" id=\"outline-link-H10\">PATHOLOGY</a><ul><li><a href=\"#H11\" id=\"outline-link-H11\">Morphology</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Immunophenotype</a></li><li><a href=\"#H13\" id=\"outline-link-H13\">Grading</a></li><li><a href=\"#H14\" id=\"outline-link-H14\">Genetic features</a></li></ul></li><li><a href=\"#H15\" id=\"outline-link-H15\">DIAGNOSIS</a></li><li><a href=\"#H16\" id=\"outline-link-H16\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H17\" id=\"outline-link-H17\">STAGING</a></li><li><a href=\"#H18\" id=\"outline-link-H18\">NATURAL HISTORY AND PROGNOSIS</a></li><li><a href=\"#H19\" id=\"outline-link-H19\">MANAGEMENT</a></li><li><a href=\"#H20\" id=\"outline-link-H20\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#H22300596\" id=\"outline-link-H22300596\">ACKNOWLEDGMENT</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"PULM/4324|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/52068\" class=\"graphic graphic_diagnosticimage\">- Lymphomatoid gran CT I</a></li><li><a href=\"image.htm?imageKey=PULM/60848\" class=\"graphic graphic_diagnosticimage\">- Lymphomatoid gran CT II</a></li><li><a href=\"image.htm?imageKey=PULM/71625\" class=\"graphic graphic_diagnosticimage\">- Lymphomatoid gran CT III</a></li></ul></li><li><div id=\"PULM/4324|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=PULM/74089\" class=\"graphic graphic_picture\">- Lymphomatoid granuloma Low</a></li><li><a href=\"image.htm?imageKey=PULM/61309\" class=\"graphic graphic_picture\">- Lymphomatoid granuloma High</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-granulomatosis-with-polyangiitis-and-microscopic-polyangiitis\" class=\"medical medical_review\">Clinical manifestations and diagnosis of granulomatosis with polyangiitis and microscopic polyangiitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-treatment-of-epstein-barr-virus-infection\" class=\"medical medical_review\">Clinical manifestations and treatment of Epstein-Barr virus infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-extranodal-nk-t-cell-lymphoma-nasal-type\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of extranodal NK/T cell lymphoma, nasal type</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-extranodal-marginal-zone-lymphoma-of-mucosa-associated-lymphoid-tissue-malt\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-pathologic-features-and-diagnosis-of-peripheral-t-cell-lymphoma-not-otherwise-specified\" class=\"medical medical_review\">Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=differential-diagnosis-and-evaluation-of-multiple-pulmonary-nodules\" class=\"medical medical_review\">Differential diagnosis and evaluation of multiple pulmonary nodules</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=epidemiology-clinical-manifestations-pathologic-features-and-diagnosis-of-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=evaluation-staging-and-response-assessment-of-non-hodgkin-lymphoma\" class=\"medical medical_review\">Evaluation, staging, and response assessment of non-Hodgkin lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=high-resolution-computed-tomography-of-the-lungs\" class=\"medical medical_review\">High resolution computed tomography of the lungs</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=infectious-mononucleosis-in-adults-and-adolescents\" class=\"medical medical_review\">Infectious mononucleosis in adults and adolescents</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=inflammatory-myofibroblastic-tumor-plasma-cell-granuloma-of-the-lung\" class=\"medical medical_review\">Inflammatory myofibroblastic tumor (plasma cell granuloma) of the lung</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=initial-treatment-of-advanced-stage-diffuse-large-b-cell-lymphoma\" class=\"medical medical_review\">Initial treatment of advanced stage diffuse large B cell lymphoma</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=lymphoid-interstitial-pneumonia-in-adults\" class=\"medical medical_review\">Lymphoid interstitial pneumonia in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=overview-of-pulmonary-function-testing-in-adults\" class=\"medical medical_review\">Overview of pulmonary function testing in adults</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=oxygenation-and-mechanisms-of-hypoxemia\" class=\"medical medical_review\">Oxygenation and mechanisms of hypoxemia</a></li></ul></div></div>","javascript":null}